CELLAVISION AB |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 227.2 SEK | -0.11% |
|
-4.81% | +7.31% |
| Apr. 25 | Transcript : CellaVision AB, Q1 2024 Earnings Call, Apr 25, 2024 | |
| Apr. 25 | CellaVision AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 7,621 | 7,322 | 7,757 | 5,462 | 5,057 | 5,426 | - | - |
| Enterprise Value (EV) 1 | 7,678 | 7,353 | 7,763 | 5,456 | 5,000 | 5,300 | 5,214 | 5,074 |
| P/E ratio | 76.8 x | 81.9 x | 61.9 x | 46.2 x | 38.8 x | 32.5 x | 25 x | 20.1 x |
| Yield | - | 0.24% | 0.62% | 0.87% | 1.06% | 1.09% | 1.32% | 1.56% |
| Capitalization / Revenue | 16.5 x | 15.5 x | 13.7 x | 8.54 x | 7.47 x | 6.97 x | 6.11 x | 5.3 x |
| EV / Revenue | 16.6 x | 15.6 x | 13.7 x | 8.53 x | 7.38 x | 6.81 x | 5.87 x | 4.96 x |
| EV / EBITDA | 52.3 x | 51.5 x | 39.6 x | 27.5 x | 24.2 x | 20.6 x | 16.6 x | 13.4 x |
| EV / FCF | 72.3 x | 117 x | 68 x | 81.1 x | 45.1 x | 38.2 x | 32.4 x | 25.9 x |
| FCF Yield | 1.38% | 0.86% | 1.47% | 1.23% | 2.22% | 2.62% | 3.08% | 3.86% |
| Price to Book | 21.9 x | 17 x | 14.3 x | 8.51 x | 7.06 x | 6.52 x | 5.55 x | 4.57 x |
| Nbr of stocks (in thousands) | 23,852 | 23,852 | 23,852 | 23,852 | 23,852 | 23,852 | - | - |
| Reference price 2 | 319.5 | 307.0 | 325.2 | 229.0 | 212.0 | 227.5 | 227.5 | 227.5 |
| Announcement Date | 2/5/20 | 2/4/21 | 2/4/22 | 2/8/23 | 2/7/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 461.8 | 471.4 | 565.6 | 639.3 | 677.3 | 778.7 | 888.6 | 1,023 |
| EBITDA 1 | 146.7 | 142.9 | 196.2 | 198.4 | 206.8 | 257.3 | 314.8 | 377.3 |
| EBIT 1 | 126.6 | 110.3 | 162.7 | 158.3 | 167.1 | 213.9 | 272.6 | 334.9 |
| Operating Margin | 27.41% | 23.39% | 28.77% | 24.75% | 24.66% | 27.47% | 30.68% | 32.73% |
| Earnings before Tax (EBT) 1 | 129.2 | 112.2 | 158.3 | 148.4 | 164.2 | 211.8 | 274.9 | 341.4 |
| Net income 1 | 99.17 | 89.48 | 125.3 | 118.3 | 130.3 | 167.3 | 217.3 | 269.5 |
| Net margin | 21.48% | 18.98% | 22.16% | 18.51% | 19.24% | 21.48% | 24.45% | 26.34% |
| EPS 2 | 4.160 | 3.750 | 5.250 | 4.960 | 5.460 | 7.000 | 9.097 | 11.30 |
| Free Cash Flow 1 | 106.2 | 63.06 | 114.2 | 67.27 | 110.9 | 138.9 | 160.8 | 196 |
| FCF margin | 23.01% | 13.37% | 20.19% | 10.52% | 16.37% | 17.84% | 18.09% | 19.16% |
| FCF Conversion (EBITDA) | 72.4% | 44.13% | 58.21% | 33.91% | 53.62% | 54% | 51.08% | 51.94% |
| FCF Conversion (Net income) | 107.12% | 70.47% | 91.11% | 56.85% | 85.11% | 83.07% | 73.99% | 72.72% |
| Dividend per Share 2 | - | 0.7500 | 2.000 | 2.000 | 2.250 | 2.473 | 3.007 | 3.550 |
| Announcement Date | 2/5/20 | 2/4/21 | 2/4/22 | 2/8/23 | 2/7/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 164.2 | 162.4 | 183.6 | 141 | 152.3 | 139.1 | 169.7 | 167.9 | 200.6 | 194 | 192.7 | 225.3 |
| EBITDA 1 | 60.49 | 59.04 | 61.48 | 29.45 | 48.4 | 34.55 | 56.03 | 43.44 | 72.79 | 63.9 | 64.97 | 83.4 |
| EBIT 1 | 51.76 | 49.82 | 52.43 | 16.96 | 39.06 | 25.04 | 46.19 | 33.27 | 62.55 | 53.62 | 54.32 | 72.45 |
| Operating Margin | 31.53% | 30.67% | 28.56% | 12.02% | 25.65% | 18% | 27.23% | 19.82% | 31.18% | 27.63% | 28.2% | 32.15% |
| Earnings before Tax (EBT) 1 | 51.04 | 48.62 | 46.86 | 12.85 | 40.09 | 24.36 | 44.34 | 32.16 | 63.37 | 54 | 51.36 | 75.26 |
| Net income 1 | 39.76 | 38.4 | 37.25 | 10.38 | 32.3 | 19.21 | 34.71 | 25.96 | 50.43 | 42.44 | 41.39 | 56.88 |
| Net margin | 24.22% | 23.64% | 20.29% | 7.36% | 21.2% | 13.81% | 20.46% | 15.46% | 25.14% | 21.87% | 21.48% | 25.24% |
| EPS 2 | 1.670 | 1.610 | 1.560 | 0.4400 | 1.350 | 0.8100 | 1.460 | 1.090 | 2.110 | 1.756 | 1.803 | 2.402 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | 2.300 |
| Announcement Date | 2/4/22 | 5/10/22 | 7/20/22 | 10/26/22 | 2/8/23 | 5/4/23 | 7/20/23 | 10/25/23 | 2/7/24 | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 57.8 | 30.5 | 6.37 | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 5.56 | 56.9 | 126 | 212 | 352 |
| Leverage (Debt/EBITDA) | 0.3936 x | 0.2136 x | 0.0325 x | - | - | - | - | - |
| Free Cash Flow 1 | 106 | 63.1 | 114 | 67.3 | 111 | 139 | 161 | 196 |
| ROE (net income / shareholders' equity) | 31.1% | 23% | 25.8% | 20% | 19.2% | 21.5% | 23.7% | 24.4% |
| ROA (Net income/ Total Assets) | - | - | - | 13.8% | 14.3% | 16.9% | 19% | 19.2% |
| Assets 1 | - | - | - | 858.5 | 910.2 | 987.1 | 1,143 | 1,402 |
| Book Value Per Share 2 | 14.60 | 18.00 | 22.80 | 26.90 | 30.00 | 34.90 | 41.00 | 49.80 |
| Cash Flow per Share | - | 2.980 | - | - | - | - | - | - |
| Capex 1 | 2.67 | 8.07 | 84.3 | 70 | 85.5 | 70 | 78.7 | 86.3 |
| Capex / Sales | 0.58% | 1.71% | 14.91% | 10.95% | 12.63% | 8.99% | 8.86% | 8.43% |
| Announcement Date | 2/5/20 | 2/4/21 | 2/4/22 | 2/8/23 | 2/7/24 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
227.5
SEK
Average target price
257.5
SEK
Spread / Average Target
+13.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.31% | 497M | |
| -13.24% | 19.22B | |
| -46.59% | 2.63B | |
| +17.50% | 1.86B | |
| -0.58% | 1.66B | |
| +24.91% | 1.23B | |
| -8.67% | 1.05B | |
| -21.91% | 894M | |
| -4.49% | 740M | |
| -17.51% | 687M |
- Stock Market
- Equities
- CEVI Stock
- Financials CellaVision AB
